RESUMEN
Pleiotrophin (PTN) is a polypeptide that belongs to a family of heparin-binding growth factor, which displays mitogenic activity for a wide variety of cells. Since PTN induces the proliferation of immune cells the mechanism of action was investigated. In the present study, we show for the first time that PTN induces the expression of inflammatory cytokines including TNF-alpha, IL-1beta and IL-6 in quiescent human peripheral blood mononuclear cells (PBMC). These results emphasize the importance of PTN in the regulation of inflammatory processes. Elucidation of the mechanisms by which a host factor such PTN regulates cytokines production will significantly advance our understanding of endothelium-immunity interactions.
Asunto(s)
Proteínas Portadoras/fisiología , Citocinas/biosíntesis , Leucocitos Mononucleares/inmunología , Proteínas Portadoras/farmacología , Citocinas/farmacología , Citocinas/fisiología , Humanos , Inflamación/inmunología , Leucocitos Mononucleares/efectos de los fármacos , Proteínas Recombinantes/farmacologíaRESUMEN
Pleiotrophin (PTN), is a heparin-dependent growth factor involved in angiogenesis and tumor growth. PTN contains a thrombospondin repeat-I (TSR-I) motif in its two beta-sheet domains that are involved in its binding to heparin and its neurite outgrowth activity. Based on the importance of the binding of PTN to heparin in its dimerization and biological activities, we have designed two synthetic peptides, P(13-39) and P(65-97) corresponding to a part of the N-terminal and C-terminal TSR-I motif of PTN, respectively. P(65-97) inhibited the mitogenic, tumorigenic and angiogenic activities of PTN, as well as the mitogenic and an angiogenic activity of fibroblast growth factor-2 (FGF-2). However, P(65-97) had no effect on the mitogenic activity of epidermal growth factor, which does not bind heparin. P(65-97) but not P(13-39) inhibited the binding of PTN and to a lesser extent of FGF-2 to heparin using an immunoassay and an optical biosensor assay and bound directly to heparin with a K(d) of 120 nM. These findings suggest that P(65-97), containing amino acids 65-97 of the TSR-I motif of the C-terminal domain of PTN, inhibits the activities of PTN and FGF-2 by virtue of its ability to bind heparin very effectively and so compete with the growth factors for their polysaccharide co-receptor.
Asunto(s)
Proteínas Portadoras/química , Citocinas/química , Mitosis/efectos de los fármacos , Neoplasias/tratamiento farmacológico , Neovascularización Fisiológica/efectos de los fármacos , Péptidos/farmacología , Trombospondinas/química , Secuencia de Aminoácidos , Animales , Neoplasias de la Mama/patología , Proteínas Portadoras/antagonistas & inhibidores , Proteínas Portadoras/genética , Línea Celular Tumoral , Movimiento Celular , Citocinas/antagonistas & inhibidores , Citocinas/genética , Endotelio Vascular/citología , Femenino , Factor 2 de Crecimiento de Fibroblastos/antagonistas & inhibidores , Factor 2 de Crecimiento de Fibroblastos/genética , Heparina/metabolismo , Humanos , Ratones , Ratones Desnudos , Datos de Secuencia Molecular , Células 3T3 NIH , Péptidos/síntesis química , Péptidos/química , Unión Proteica , Proteínas Recombinantes/antagonistas & inhibidores , Proteínas Recombinantes/biosíntesis , Proteínas Recombinantes/química , Proteínas Recombinantes/aislamiento & purificación , Trasplante Heterólogo , Venas Umbilicales/citologíaRESUMEN
To better understand the particular vulnerability of mesencephalic dopaminergic neurons to toxins or gene mutations causing parkinsonism, we have taken advantage of a primary cell culture system in which these neurons die selectively. Antimitotic agents, such as cytosine arabinoside or cAMP, prevent the death of the neurons by arresting astrocyte proliferation. To identify factors implicated in either the death of the dopaminergic neurons or in the neuroprotective effect of cAMP, we constructed cDNA libraries enriched by subtractive hybridization and suppressive PCR in transcripts that are preferentially expressed in either control or cAMP-treated cultures. Differentially expressed transcripts were identified by hybridization of the enriched cDNAs with a commercially available cDNA expression array. The proteoglycan receptors syndecan-3 and the receptor protein tyrosine phosphatase zeta/beta were found among the transcripts preferentially expressed under control conditions, and their ligand, the cytokine pleiotrophin, was highly represented in the cDNA libraries for both conditions. Since pleiotrophin is expressed during embryonic and perinatal neural development and following lesions in the adult brain, we investigated its role in our cell culture model. Pleiotrophin was not responsible for the death of dopaminergic neurons under control conditions, or for their survival in cAMP-treated cultures. It was, however, implicated in the initial and cAMP-dependent enhancement of the differentiation of the dopaminergic neurons in our cultures. In addition, our experiments have provided evidence for a cAMP-dependent regulatory pathway leading to protease activation, and the identification of pleiotrophin as a target of this pathway.
Asunto(s)
Proteínas Portadoras/genética , AMP Cíclico/metabolismo , Citocinas/genética , Degeneración Nerviosa/metabolismo , Factores de Crecimiento Nervioso/metabolismo , Neuronas/metabolismo , Sustancia Negra/metabolismo , Animales , Proteínas Portadoras/fisiología , Células Cultivadas , Citocinas/fisiología , Dopamina/metabolismo , Resistencia a Medicamentos/genética , Activación Enzimática/fisiología , Perfilación de la Expresión Génica , Regulación de la Expresión Génica/fisiología , Biblioteca de Genes , Predisposición Genética a la Enfermedad/genética , Glicoproteínas de Membrana/genética , Degeneración Nerviosa/patología , Degeneración Nerviosa/fisiopatología , Proteínas del Tejido Nervioso/genética , Neuronas/patología , Análisis de Secuencia por Matrices de Oligonucleótidos , Trastornos Parkinsonianos/metabolismo , Trastornos Parkinsonianos/patología , Trastornos Parkinsonianos/fisiopatología , Péptido Hidrolasas/metabolismo , Proteínas Tirosina Fosfatasas/genética , Proteoglicanos/genética , Ratas , Proteínas Tirosina Fosfatasas Clase 5 Similares a Receptores , Sustancia Negra/patología , Sustancia Negra/fisiopatología , Sindecano-3RESUMEN
Heparin affin regulatory peptide (HARP) and midkine (MK) are growth factors, expressed in carcinomas, neuroblastomas and gliomas. In this study, we measured the levels of HARP and MK in plasma samples from 77 cancer patients. The patients had advanced tumors with loco-regional (n=18) or metastatic (n=49) diseases and 10 patients have their diseases limited to the primary site. HARP and MK plasma concentrations were significantly higher in all of these different subgroups of cancer patients (P<0.05 in all cases), when compared to healthy controls (n=30). Neither HARP nor MK levels were significantly different between patients with loco-regional and metastatic tumors (P=0.203 and 0.242, respectively). Moreover, a strong correlation between the elevations of the plasma levels of these two proteins (r2=0.546) in these cancer patients was found. Measurements of these secreted angiogenic growth factors may be useful for evaluation of cancer diagnosis.
Asunto(s)
Biomarcadores de Tumor/sangre , Neoplasias/sangre , Adulto , Anciano , Anciano de 80 o más Años , Proteínas Portadoras/sangre , Citocinas/sangre , Ensayo de Inmunoadsorción Enzimática , Femenino , Sustancias de Crecimiento/sangre , Humanos , Masculino , Persona de Mediana Edad , Midkina , Neoplasias/patologíaRESUMEN
Heparin affin regulatory peptide (HARP) is a heparin binding growth factor that belongs to a family of molecule whose biological function in myogenesis has been suspected without formal demonstration. In the present study, we investigated the expression and the distribution of HARP and its mRNA during soleus muscle regeneration using a crushed-induced regeneration model and also during differentiation of muscle satellite cells in primary cultures. We show that HARP mRNA and protein expression are increased during the regeneration process with a peak at day 5 after muscle crushing when new myotubes are formed. In situ hybridization and immunohistochemical studies showed that activated myoblasts expressed HARP at day two after crushing. Five days after muscle lesion, HARP is localised in newly formed myotubes as well as in prefused activated myoblasts. In regenerated myofibers, 15 days after crushing, expression of HARP was reduced. In vitro experiments using primary cultures of rat satellite cells indicated that HARP expression level increased during the differentiation process and peaked on fusion of myoblasts into myotubes. This is the first study demonstrating the presence of HARP in fusing myogenic cells suggests that this growth factor could play a function in myogenic differentiation.
Asunto(s)
Proteínas Portadoras/metabolismo , Citocinas/metabolismo , Desarrollo de Músculos/fisiología , Músculo Esquelético/metabolismo , Regeneración/fisiología , Animales , Proteínas Portadoras/análisis , Proteínas Portadoras/genética , Citocinas/análisis , Citocinas/genética , Inmunohistoquímica , Hibridación in Situ , Técnicas In Vitro , Desarrollo de Músculos/genética , Músculo Esquelético/fisiología , Mioblastos/metabolismo , Miogenina/genética , Miogenina/fisiología , ARN Mensajero/análisis , ARN Mensajero/genética , ARN Mensajero/metabolismo , Ratas , Ratas Wistar , Células Satélite del Músculo Esquelético/química , Factores de Tiempo , Regulación hacia Arriba/fisiologíaRESUMEN
Heparin affin regulatory peptide (HARP) is an heparin-binding growth factor, highly expressed in several primary human tumors and considered as a rate-limiting angiogenic factor in tumor growth, invasion, and metastasis. Implication of this protein in carcinogenesis is linked to its mitogenic, angiogenic, and transforming activities. Recently, we have demonstrated that the C-terminal residues 111-136 of HARP are required for its mitogenic and transforming activities (Bernard-Pierrot, I., Delbe, J., Caruelle, D., Barritault, D., Courty, J., and Milhiet, P. E. (2001) J. Biol. Chem. 276, 12228-12234). In this paper, HARP deleted of its last 26 amino acids was shown to act as a dominant negative effector for its mitogenic, angiogenic, transforming, and tumor-formation activities by heterodimerizing with the wild type protein. Similarly, the synthetic corresponding peptide P111-136 displayed in vitro inhibition of wild type HARP activities, but in this case, the inhibition was mainly explained by the competition of the peptide with HARP for the binding to the extracellular domain of the high affinity ALK receptor.
Asunto(s)
Proteínas Portadoras/fisiología , Transformación Celular Neoplásica , Citocinas/fisiología , Endotelio Vascular/fisiología , Sustancias de Crecimiento/fisiología , Neoplasias/prevención & control , Neovascularización Fisiológica/fisiología , Fragmentos de Péptidos/farmacología , Células 3T3 , Secuencia de Aminoácidos , Animales , Antineoplásicos/farmacología , Aorta , Proteínas Portadoras/química , Proteínas Portadoras/genética , Citocinas/química , Citocinas/genética , Replicación del ADN , Endotelio Vascular/efectos de los fármacos , Humanos , Cinética , Ratones , Ratones Desnudos , Datos de Secuencia Molecular , Neoplasias/irrigación sanguínea , Neovascularización Fisiológica/efectos de los fármacos , Fragmentos de Péptidos/química , Proteínas Recombinantes/metabolismoRESUMEN
Heparin-affin regulatory peptide (HARP) and Midkine (MK) belong to a family of growth/differentiation factors that have a high affinity for heparin. The involvement of these molecules in various proliferative diseases prompted us to develop an assay for measuring the concentrations of these factors in biological fluids and culture media. This report describes an immunoassay that uses only commercially available materials, based on the high affinity of certain molecules for heparin. It consists of adsorbing heparin-BSA covalent complexes to microtiter plate wells and to quantify the heparin bound HARP or MK by using appropriate antibody. The method is specific and measures concentrations ranging from 40-1200 pg/mL HARP and from 25-1200 pg/mL MK and various parameters are investigated. The within-assay coefficient of variation was less than 5% for both assays. The method was checked by measuring the concentrations of these growth factors in the sera of healthy humans and in patients with cancer. As previously reported, we confirmed that the serum concentrations of MK are higher in patients with tumours (n = 139) than in controls (n = 19). The synthesis of HARP and MK by various cells in culture was also analysed.